Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201
Autor: | Kirsten E. Wiens, Sylvester Maleghemi, Bior K. Bior, Vanessa Sanchez, Clare Fraser, Damien Slater, Richard Lako, Olushayo Olu, Forrest K. Jones, Argata Guracha Guyo, Lul Deng, Maya N. Demby, Iboyi Amanya Jacob, Rachel Mills, Juma John Hassen, Jason B. Harris, Serina Moheed, Andrea Caflisch, Justin Lessler, Pinyi Nyimol Mawien, Sheila K. Baya, Andrew Baguma, John Rumunu, Joseph F. Wamala, Andrew S. Azman, Richelle C. Charles |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Microbiology (medical)
sub-Saharan Africa medicine.medical_specialty Epidemiology Cross-sectional study serosurvey 030231 tropical medicine Population Juba Disease medicine.disease_cause Serology 03 medical and health sciences respiratory infections 0302 clinical medicine Internal medicine medicine Credible interval Seroprevalence antibodies viruses 030212 general & internal medicine education South Sudan Coronavirus Original Research education.field_of_study seroprevalence business.industry SARS-CoV-2 Research virus diseases COVID-19 Seroepidemiologic Studies Infectious Diseases coronavirus disease business influenza Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba South Sudan 2020 severe acute respiratory syndrome coronavirus 2 |
Zdroj: | Emerging Infectious Diseases |
ISSN: | 1080-6059 1080-6040 |
Popis: | Relatively few COVID-19 cases and deaths have been reported through much of sub-Saharan Africa, including South Sudan, although the extent of SARS-CoV-2 spread remains unclear due to weak surveillance systems and few population-representative serosurveys.We conducted a representative household-based cross-sectional serosurvey in Juba, South Sudan. We quantified IgG antibody responses to SARS-CoV-2 spike protein receptor-binding domain and estimated seroprevalence using a Bayesian regression model accounting for test performance.We recruited 2,214 participants from August 10 to September 11, 2020 and 22.3% had anti-SARS-CoV-2 IgG titers above levels in pre-pandemic samples. After accounting for waning antibody levels, age, and sex, we estimated that 38.5% (32.1 - 46.8) of the population had been infected with SARS-CoV-2. For each RT-PCR confirmed COVID-19 case, 104 (87-126) infections were unreported. Background antibody reactivity was higher in pre-pandemic samples from Juba compared to Boston, where the serological test was validated. The estimated proportion of the population infected ranged from 30.1% to 60.6% depending on assumptions about test performance and prevalence of clinically severe infections.SARS-CoV-2 has spread extensively within Juba. Validation of serological tests in sub-Saharan African populations is critical to improve our ability to use serosurveillance to understand and mitigate transmission. |
Databáze: | OpenAIRE |
Externí odkaz: |